Scientist I, Bioanalytical – Drug Antibody Conjugates (DACs)

The role

This person will lead bioanalytical strategies for the discovery and development of next-generation degrader antibody conjugates. They will focus on LC-MS/MS and hybrid assay strategies for quantitative and qualitative analysis across in vitro and in vivo studies.

What you will do

• Lead development, qualification, and execution of bioanalytical methods for DAC modalities.
• Design and implement LC-MS/MS-based workflows using Sciex platforms.
• Apply high-resolution mass spectrometry platforms for DAC characterization and metabolite identification.
• Develop hybrid LBA–LC-MS/MS strategies.
• Design, execute and interpret in vitro studies.
• Lead bioanalytical support for in vivo studies.
• Characterize biotransformation pathways of DACs.
• Partner with DMPK, Proteomics, Pharmacology and Chemistry teams.
• Author and review technical reports, regulatory documentation, and study summaries.
• Troubleshoot analytical challenges and mentor junior scientists.

Required qualifications

• Ph.D. with 5+ years or M.S. with 8+ years of relevant industry experience in Bioanalysis, Analytical chemistry, or related field.
• Deep expertise in LC-MS/MS bioanalysis, including method development, qualification/validation, and troubleshooting for complex modalities.
• Proven experience with Sciex platforms (e.g., 7600 ZenoTOF, 6500+, 7500) and high-resolution MS.
• Strong background in ADCs, DACs, or related bioconjugates, including characterization and payload quantitation.
• Experience supporting both in vitro ADME and in vivo PK studies, with demonstrated ability to interpret integrated datasets.
• Proficiency in sample preparation techniques for large molecules and bioconjugates (e.g., immunocapture, enzymatic digestion, hybrid workflows).
• Strong data analysis, visualization, and reporting skills (e.g., vendor software, GraphPad Prism).
• Excellent written and verbal communication skills, with experience in technical documentation.
• Ability to work in a fast-paced, collaborative environment and manage multiple priorities.

Nice to have

• Experience in targeted protein degradation or heterobifunctional degrader platforms.
• Experience with hybrid LBA–LC-MS/MS assays and ligand-binding assays (ELISA, MSD).
• Understanding of linker chemistry, conjugation strategies, and degradation mechanisms for bioconjugates.
• Exposure to regulatory bioanalytical guidance (FDA, EMA) for large molecules and conjugates.

About the company

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines. The company uses an AI-integrated discovery engine to develop treatments for cancer and inflammatory diseases.